GH treatment is not appropriate for cancer patients. If you develop cancer or tumors while undergoing GH therapy, you will need to immediately desist from treatment. GH therapy is also not appropriate to stimulate growth in children who have already stopped growing naturally.
GH therapy can never be used in response to critical illness as a result of respiratory distress or failure, heart or abdominal surgery, or massive trauma.
If the patient is a diabetic, the doctor will need to closely monitor the dosage of insulin. GH therapy can influence the body’s reaction to insulin, and the dosage of insulin may need to be modified.
The doctor will need to be made aware of any and all other prescription and over the counter medications being taken by a patient undergoing GH therapy.
GH treatment can cause intra cranial hypertension in a very small proportion of patients. This can be serious, and you should seek immediate medical attention if you experience nausea, headache, visual changes, and or vomiting while taking GH.
Pregnant women and nursing mothers will need to discuss the possibilities of treatment during this period with their doctor.
Side effects of GH therapy are usually mild to moderate. Some more common side effects are, water retention, joint stiffness or joint swelling and a tingling in the arms. These side effects will usually present in the first weeks of treatment, and can usually be eliminated through dosage modification.
Anyone undergoing GH therapy should read the full patient information and drug information materials given with the drug.
The information presented on this site is to be used as an informational resource only, and should never be used as a substitute for a professional medical consultation and diagnosis. Never medically self diagnose. Your doctor or health care worker must evaluate and work with you to determine if you need a certain course of treatment, and to then manage and evaluate the ongoing treatment.
Genevatropin® is a pharmacy compounded product and is currently not approved by the US Food and Drug Administration. Genevatropin® does not require a NDA or
ANDA by the FDA because of its current status as a compounded pharmaceutical. This site is for educational purposes only and not to be utilized as medical advice.